NTLAIntellia Therapeutics, Inc.
$13.08-16% 1Y
$13.08
$8.0452 weeks$27.98
Latest close: back above its 200-day averageOct 9, 2026what changed →
Is the price fair?
What NTLA's price assumes
Intellia Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 33.1× revenue.
33.1
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 3.34
Price / book · today's price, fiscal year to Dec 31, 2025
- EV / sales
- 26.4
EV / sales
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 3.34
- EV / EBIToperating margin −712%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 26.4
- Market capitalisation
- $2.24B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks